Directives Nationales de Prise en Charge du Diabète

Objectives

The 2023 national guidelines for diabetes care in Côte d’Ivoire provide an updated, nationally adapted framework for preventing, detecting and managing diabetes, principally uncomplicated type 2 diabetes, within the National Programme for the Control of Metabolic Diseases and Prevention of Non-Communicable Diseases and the wider universal health coverage agenda. They seek to standardise care across health-system levels, improve quality and cost-effectiveness, reduce morbidity, premature mortality and social burden, and strengthen patients’ capacity for self-management.[1][2][3][4][5]

• Address diabetes and related non-communicable diseases in the context of urbanisation, physical inactivity, obesity, metabolic syndrome and their cardiovascular, renal, cerebrovascular and peripheral vascular consequences.[1][6]
• Provide clinical and preventive guidance adapted to Côte d’Ivoire for health workers delivering primary healthcare, while organising more complex assessment and treatment at secondary and specialist levels.[2][7][8]
• Confirm diabetes biochemically before treatment in people without unequivocal hyperglycaemia, assess cardiovascular risk and complications, and select treatment according to clinical status and risk.[9][7]
• Improve quality of life and productivity through early diagnosis, prevention or reduction of acute and chronic morbidity, prevention of premature deaths, patient education, self-management and family involvement.[4][5][10]
• Promote therapeutic targets for glycaemia, glycated haemoglobin, body mass index, blood pressure and blood lipids, including a general glycated haemoglobin target below 7%, while allowing targets to be individualised for risk, comorbidity, frailty and life expectancy.[5][11]
• Prioritise healthy balanced diets, regular physical activity, weight management, smoking cessation, therapeutic education and culturally appropriate behaviour change as core components of diabetes prevention and management.[5][12][13][14][15]
• Detect overt and latent diabetes among people with symptoms and those at elevated risk, including people with family history, age above 45 years, obesity, hypertension, dyslipidaemia, cardiovascular or renal disease, adverse pregnancy history, inactivity, tobacco or alcohol use, or polycystic ovary syndrome.[6][16]
• Integrate management of diabetes with hypertension, dyslipidaemia, metabolic syndrome, chronic kidney disease and acute metabolic complications, including hypoglycaemia, diabetic ketoacidosis and hyperosmolar states.[17][18][19][20][21][22]

Implementation

Implementation uses a tiered health-system model, supported by nationally coordinated multidisciplinary guideline development and evidence review. Primary facilities provide screening, diagnosis, routine follow-up, lifestyle support and specified treatments, while hospitals and specialist services manage complex disease, advanced investigations, treatment intensification and referrals. The available extracts describe substantial clinical monitoring and referral arrangements, but do not specify a programme-wide indicator set, reporting system, implementation timetable, budget or formal accountability framework.[23][3][7][8][4][24][25][14]

• Coordinate guideline development through an updating committee, steering committee and multidisciplinary expert committee, using prior national directives, primary-care manuals, International Diabetes Federation evidence and health-facility standards; adapt recommendations through expert discussion and consensus validation.[23]
• Engage health providers, community health workers, non-governmental organisations, planners, social and education services, national and international health-programme personnel, specialist clinicians, nutrition professionals and Ministry-linked programme structures.[2][3]
• Deliver primary care through dispensaries, health centres and urban health facilities staffed by general practitioners, nurses, midwives, auxiliary staff and community health workers; deliver secondary multidisciplinary care through general and regional hospitals.[7][8]
• Equip primary facilities with glucose meters and strips, blood-pressure monitors, urine strips, anthropometric equipment, foot-assessment tools, and glucose and creatinine testing; strengthen secondary facilities with eye equipment, electrocardiography, glycated haemoglobin, lipid, renal and liver-function testing.[8]
• Schedule initial and periodic consultations, including visits at months 1, 2, 3, 6, 9 and 12 and annual review, with history-taking, anthropometry, blood-pressure measurement, foot and oral examination, laboratory testing, education and treatment review.[8][4]
• Apply stepped pharmacological management: begin with lifestyle measures and metformin where appropriate, progress to dual or triple therapy or insulin when targets are not achieved, and take account of contraindications, cardiovascular risk, medicine access and patients’ economic circumstances.[26][27][24]
• Refer people with severe hyperglycaemia, ketones, pregnancy, infection, poor general condition, treatment failure, suspected secondary hypertension, advanced kidney risk or uncontrolled disease to higher-level or specialist care; return controlled patients to lower-level services where indicated.[17][28][29][25][30]
• Implement community and facility screening through preparation of registers, clinical guides and testing supplies; inform leaders and target populations, conduct risk and clinical assessment, provide individual or group education in local languages where needed, and initiate treatment or referral for detected cases.[16][14][15]
• Monitor clinical care through diagnostic confirmation, repeat testing for normal results within no more than three years, glycated haemoglobin reassessment after three months, blood-pressure measurement at consultations, lipid monitoring, renal monitoring, treatment-target review and safety monitoring during exercise, insulin treatment and acute emergencies.[9][24][17][29][31][32][33]

Monitoring & Evaluation

The guideline’s monitoring emphasis is principally clinical: it combines diagnostic confirmation, scheduled follow-up, measurement against therapeutic targets, risk assessment, complication screening, treatment reassessment and referral across levels of care. It does not establish a documented programme-level indicator framework, routine reporting system, surveillance architecture, audit process or formal implementation-accountability mechanism in the available extracts.[23][3]

• Confirm an abnormal glucose result promptly in asymptomatic people using repeat fasting or random glucose measurements, and repeat normal testing at intervals of no more than three years.[9][7]
• Assess cardiovascular risk before selecting treatment for every person with type 2 diabetes, including established cardiovascular disease, organ damage, age, hypertension, dyslipidaemia, smoking and obesity.[7]
• Schedule initial, quarterly and annual reviews, with primary-care consultations also listed at months 1, 2, 3, 6, 9 and 12.[8][4]
• Record clinical findings at follow-up, including anthropometry, waist circumference, blood pressure, foot and oral examination, blood glucose, urine testing, treatment review and patient education.[8][4]
• Use investigations according to care level and visit schedule, including glucose, urine glucose, ketones and protein, creatinine, sodium, potassium, lipid profile, glycated haemoglobin, estimated glomerular filtration rate, eye examination and electrocardiography.[4]
• Assess treatment against clinical targets, including glycated haemoglobin generally below 7%, fasting capillary glucose of 0.80 to 1.30 grams per litre, post-prandial glucose below 1.80 grams per litre, and blood pressure generally below 130/80 millimetres of mercury.[5]
• Reassess glycated haemoglobin after three months and maintain or intensify glucose-lowering treatment according to whether the result is below or above 7%.[24][28]
• Measure blood pressure at every consultation, assess hypertension stage and cardiovascular risk, investigate suspected secondary causes, and refer cases requiring further assessment.[17][28]
• Reassess blood-pressure treatment after three months against a target below 130/80 millimetres of mercury, escalating treatment or referring patients when targets are not met.[25][31]
• Monitor lipid profiles annually when normal and every three to six months when abnormal or during treatment.[31]
• Monitor creatinine and potassium at least annually, more frequently with renal impairment, and refer people with a glomerular filtration rate below 70 millilitres per minute per square metre to a specialist.[29]
• Use chronic kidney disease risk categories based on estimated glomerular filtration rate and albuminuria to guide annual screening, treatment and nephrology referral.[22][30]
• Evaluate therapeutic education programmes and adjust them as appropriate; support patients and families to understand targets, self-manage diabetes and prevent foot ulcers, amputations and chronic complications.[10]
• Monitor blood glucose before and after planned intense exercise because of delayed hypoglycaemia risk.[13][10]
• Monitor blood glucose during insulin initiation and provide counselling on self-monitoring, hypoglycaemia, intercurrent illness, diet and physical activity.[34]
• Recheck blood glucose 15 minutes after treatment of hypoglycaemia, repeating glucose administration where necessary and aiming to confirm a value above 0.70 grams per litre.[32][35]
• Monitor hyperglycaemic emergencies through glucose, electrolytes and anion gap, creatinine, osmolality, blood gases, ketones, hydration, consciousness, precipitating factors and complications.[21][36]
• Monitor consciousness, hydration, glycosuria, acetonuria, blood pressure and, where possible, capillary and venous glucose, electrolytes and blood gases during ketoacidosis management.[37][33]

Costing & Financing

The guideline recognises diabetes as a condition with substantial financial consequences and seeks care that is cost-effective, but the extracts provide no implementation budget, national allocation, financing plan, funding source, resource-mobilisation strategy, quantified funding gap or economic model for Côte d’Ivoire.[1][2]

• Identify minimum staffing, equipment, laboratory capacity, training, patient education and facility requirements across primary and secondary care, without assigning monetary values to these inputs.[8][4]
• Consider access to medicines and the patient’s economic circumstances when selecting oral glucose-lowering treatment.[27]
• Minimise expenditure on new equipment and materials for physical-activity programmes where possible.[13]
• Regard specialist dietary products marketed for people with diabetes as potentially costly but non-essential.[12]
• Report worldwide healthcare expenditure on diabetes as increasing from 760 billion United States dollars to 966 billion United States dollars over the preceding 15 years; the source also reports a 316% figure, without supplying sufficient detail to reconcile these figures.[1]
• Link treatment initiation for symptomatic or clinically apparent cases to the Couverture Maladie Universelle, but do not specify its benefit package, reimbursement arrangements or financial coverage in the available extract.[38]
• Specify clinical quantities for emergency treatment, such as six litres of fluid over 24 hours for a 60-kilogram patient, but do not present these quantities as costs.[36]